Verona Pharma

119 articles with Verona Pharma

• Verona Pharma plc Operational Update and Financial Results for the Three and Nine Months Ended September 30, 2020

  10/29/2020

  Verona Pharma plc, a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces financial results for the three and nine months ended September 30, 2020 and provides a corporate update.

• Verona Pharma to Announce Interim Results for the Three and Nine Months Ended September 30, 2020 and Provide Corporate Update

  10/22/2020

  Verona Pharma plc announces that it will report its unaudited financial results for the three and nine months ended September 30, 2020 on Thursday, October 29, 2020 and host an investment community conference call at 9:00 a.m. EDT / 1:00 p.m. GMT to discuss these financial results and provide a corporate update.

• Verona Pharma to Present Phase 2b COPD Symptom and Quality of Life Data with Ensifentrine at CHEST 2020Posters highlight ensifentrine’s potential to provide rapid benefits

  10/13/2020

  Verona Pharma plc, a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will present new analyses from a Phase 2b clinical trial with nebulized ensifentrine in chronic obstructive pulmonary disease at CHEST Annual Meeting 2020 taking place on October 18-21.

• Verona Pharma Initiates Pilot Study with pMDI Ensifentrine in U.S. Patients Hospitalized with COVID-19

  9/8/2020

  Verona Pharma plc, a clinical-stage biopharmaceutical company focused on respiratory diseases, announces the initiation of a pilot study to investigate the efficacy and safety of ensifentrine delivered via pressurized metered-dose inhaler formulation in U.S. patients hospitalized with COVID-19.

• Verona Pharma to Present at H.C. Wainwright 22nd Annual Global Virtual Investment Conference

  9/2/2020

  Verona Pharma plc, a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Chief Executive Officer and President, will present a company overview at the H.C. Wainwright 22nd Annual Global Virtual Investment Conference on Monday, September 14, 2020 at 5:00 PM ET.

• Verona Pharma to Present Phase 2b data with Ensifentrine in COPD at the European Respiratory Society International Congress 2020New subgroup analysis supports ensifentrine’s efficacy in symptomatic COPD patients

  8/24/2020

  Verona Pharma plc, a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will present new subgroup analysis from Phase 2b trials with nebulized ensifentrine in chronic obstructive pulmonary disease at the European Respiratory Society International Congress on Tuesday, September 8, 2020.

• Verona Pharma Initiates Multiple Dose Part of Phase 2 Clinical Trial with pMDI Formulation of Ensifentrine in COPDResults expected in the first half of 2021

  8/19/2020

  Verona Pharma plc, a clinical-stage biopharmaceutical company focused on respiratory diseases, announces the initiation of the second, multiple dose, part of a Phase 2 trial to evaluate the pressurized metered-dose inhaler formulation of ensifentrine in patients with moderate to severe chronic obstructive pulmonary disease.

• Verona Pharma plc Operational Update and Financial Results for the Three and Six Months Ended June 30, 2020

  8/14/2020

  Verona Pharma plc, a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces financial results for the three and six months ended June 30, 2020 and provides a corporate update.

• Verona Pharma Announces August 2020 Virtual Investor Conference Participation

  8/3/2020

  Verona Pharma plc, a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Chief Executive Officer and President, and Mark Hahn, Chief Financial Officer, will present a company overview at the following virtual investor conferences in August 2020

• Verona Pharma to Announce Interim Results for the Three and Six Months Ended June 30, 2020 and Provide Corporate Update

  7/30/2020

  Verona Pharma plc, a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its audited financial results for the three and six months ended June 30, 2020 on Friday, August 14, 2020 and host an investment community conference call at 9:00 a.m. EDT / 2:00 p.m.

• Verona Pharma Announces FDA Response to End-of-Phase 2 Briefing Package for Ensifentrine in COPD and Outlines Phase 3 ENHANCE Clinical Program

  5/14/2020

  Verona Pharma plc announces that it has received written comments from the U.S. Food and Drug Administration in response to its End-of-Phase 2 briefing package for nebulized ensifentrine as a maintenance treatment for chronic obstructive pulmonary disease.

• Verona Pharma Presents Expanded Analysis of Ensifentrine Clinical Data in COPD Maintenance Treatment at the American Thoracic Society 2020 International Conference

  5/1/2020

  Analysis supports ensifentrine’s efficacy in COPD as monotherapy and on top of standard of care treatment in patients who remain symptomatic Six abstracts accepted demonstrating ensifentrine’s potential across treatment settings and formulations LONDON, May 01, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that six abstracts presenting clinically relevant findi

• Verona Pharma plc: Operational Update and Financial Results for the Three Months Ended March 31, 2020

  4/30/2020

  Reported positive Phase 2b results in symptomatic patients with moderate to severe COPD with nebulized ensifentrine

• Verona Pharma to Announce Financial Results for the Three Months Ended March 31, 2020 and Provide Corporate Update

  4/23/2020

  Verona Pharma plc, a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its audited financial results for the three months ended March 31, 2020 on Thursday, April 30, 2020 and host an investment community conference call at 9:00 a.m. EDT / 2:00 p.m.

• Verona Pharma plc: Results of AGM

  4/16/2020

  LONDON, April 16, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces that all resolutions proposed at the Annual General Meeting held today were duly approved by shareholders by way of a poll. The results of the poll are available on the Investors section of the Company’s website, www.veronapharma.com. About Ver

• Update on AGM Procedure

  4/8/2020

  Verona Pharma plc, a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, provides an update on its upcoming Annual General Meeting, scheduled to be held at the offices of Shakespeare Martineau at 60 Gracechurch Street, London EC3V 0HR, United Kingdom at 10.30 a.m. on April 16, 2020.

• Verona Pharma Reports Positive Efficacy and Safety Data with Single Dose pMDI Formulation of Ensifentrine in COPD

  3/31/2020

  Verona Pharma plc, a clinical-stage biopharmaceutical company focused on respiratory diseases, announces positive efficacy and safety data with a single dose of pressurized metered-dose inhaler formulation of ensifentrine in a Phase 2 clinical trial in patients with moderate to severe chronic obstructive pulmonary disease.

• 2019 Annual Report and Accounts and Notice of AGM

  3/16/2020

  Verona Pharma plc, a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, is pleased to confirm that a hard copy of the Annual Report and Accounts for the year ended December 31, 2019, the Notice of Annual General Meeting and a Form of Proxy have been mailed to Shareholders of record as of March 13, 2020.

• Verona Pharma Reports Financial Results for the Full Year Ended December 31, 2019 and Provides Corporate Update

  2/27/2020

  Post-period end, reported positive top-line Phase 2b results with nebulized ensifentrine and senior management changes

• Verona Pharma plc to Announce Financial Results for Full Year Ended December 31, 2019 and Provide Corporate Update

  2/21/2020

  LONDON, Feb. 21, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases,  announces that it will report its audited financial results for the full year ended December 31, 2019 on Thursday, February 27, 2020 and host an investment community conference call at 9:00 a.m. EST / 2:00 p.m. GMT to discuss the full year financial results and provide a corporate update. To participate, please d